Silibinin - Rottapharm Madaus

Drug Profile

Silibinin - Rottapharm Madaus

Alternative Names: Legalon; Legalon SIL

Latest Information Update: 25 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rottapharm Madaus
  • Developer Rottapharm Madaus; University of Leipzig
  • Class Antidotes; Antivirals; Chromans; Dioxins; Hepatoprotectants
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis C
  • New Molecular Entity No

Highest Development Phases

  • Marketed Liver disorders; Poisoning
  • Phase II Hepatitis C

Most Recent Events

  • 04 Mar 2015 Rottapharm Madaus withdraws the phase II/III HEPASIL trial prior to enrolment for Hepatitis C (treatment-naive) in Egypt (NCT01871662)
  • 19 Feb 2015 University of Leipzig completes a phase II trial in Hepatitis C (Adjunctive treatment, Treatment-experienced) in Germany (EudraCT2012-004442-15) before February 2015
  • 20 Jan 2015 Rottapharm Madaus discontinues a phase II pharmacokinetics trial of silibinin, alone or in combination with ribavirin, in patients with chronic hepatitis C undergoing liver transplantation (EudraCT2012-000281-38), sometime before January 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top